The effect of SGLT2 inhibitors on cardio-electrophysiological balance index in diabetic patients with preserved ejection heart failure

Authors : Gökhan GÖKALP, Nail Burak ÖZBEYAZ

Pages : 192-197

Doi:10.47482/acmr.1346676

View : 37 | Download : 41

Publication Date : 2023-09-27

Article Type : Research Paper

Abstract :Background: Type 2 diabetes mellitus insert ignore into journalissuearticles values(DM); increases the risk of heart failure with preserved ejection fraction insert ignore into journalissuearticles values(HFpEF);. The use of sodium-glucose co-transporter-2 insert ignore into journalissuearticles values(SGLT-2); inhibitors, which have been shown to have cardioprotective effects in HFpEF, has increased in frequency. The index of cardio-electrophysiological balance insert ignore into journalissuearticles values(iCEB); is a marker that can be calculated on electrocardiography insert ignore into journalissuearticles values(ECG); and has been proven to be a good predictor of ventricular arrhythmia. This study aimed to investigate the effects of SGLT-2 inhibitors on iCEB and iCEBc in type 2 DM patients with HFpEF. Methods: We retrospectively analyzed the data of 76 patients with type 2 DM with HFpEF who were started on SGLT-2 inhibitors. We compared the ECG parameters obtained at baseline and six-month follow-up. Results: The mean age of the patients included in the study was 64.7±8.9 years. When ECG parameters before and after treatment were compared, iCEB insert ignore into journalissuearticles values(4.33±1.95 vs. 4.24±1.50, p= 0.006); and iCEBc insert ignore into journalissuearticles values(4.67±1.35 vs. 4.59±1.36, p<0.001); values were found to be decreased compared to before treatment. Conclusion: The iCEB and iCEBc values of the patients decreased significantly after SGLT-2 inhibitors. These results suggest that SGLT-2 inhibitors may reduce the risk of ventricular arrhythmia in patients with HFpEF.
Keywords : diabetes mellitus, index of cardiac electrophysiological balance, sodium glucose co transporter 2 inhibitors, preserved ejection fraction heart failure